Atopic Dermatitis
Clinical Pathways promote evidence based, safe, and high-value care for patients by providing clinical recommendations and standard processes. They are developed by multidisciplinary committees of subject matter experts, informed by methodical review of available evidence and consensus among committee members.
Clinical Pathways:
- Atopic Dermatitis: Noninfected Algorithm
- Atopic Dermatitis: Infected Algorithm
- Atopic Dermatitis Synopsis (provides care standards employed for this clinical pathway)
- Guide (This provides visual cues to assist clinicians in determining the disease severity)
Inclusion criteria:
- Patients with atopic dermatitis.
Clinical Pathway Revision Representation:
- Rebecca Flynn, CPNP-PC | Dermatology | Committee Chair
- Amy Nopper, MD |Dermatology |Committee Member
- Mary Nguyen Jacobson, MD |Allergy, Asthma and Immunology |Committee Member
- Aarti Pandya, MD |Allergy, Asthma and Immunology |Committee Member
- Bridget Albani, LSCSW |Patient Experience Team | Committee Member
EBP Committee Members:
- Kathleen Berg, MD, FAAP |Evidence Based Practice
- Jarrod Dusin, PhD, RD, CPHQ |Evidence Based Practice
Publication dates:
- Finalized date: April 2026
- Next expected revision date: 2029
If you have any questions regarding this content, or identify a broken link, please email evidencebasedpractice@cmh.edu.
These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.